Literature DB >> 25850393

Reduced expression of miRNA-1237-3p associated with poor survival of spinal chordoma patients.

Ming-Xiang Zou1, Wei Huang, Xiao-Bin Wang, Jing Li, Guo-Hua Lv, Bing Wang, You-Wen Deng.   

Abstract

PURPOSE: Aberrant expression of miRNAs has been demonstrated to contribute to human carcinogenesis. This study was aimed at profiling differentially expressed miRNAs in formalin-fixed and paraffin-embedded tissues of spinal chordoma and testing the potential for using altered expression of miRNAs as prognostic markers for spinal chordoma patients.
METHODS: A miRNA array was used to profile differentially expressed miRNAs in spinal chordoma and nucleus pulposus tissues. Four of these differentially expressed miRNAs was then validated in spinal chordoma and control patients using quantitative RT-PCR. Bioinformatical analysis identified potential GO terms and signaling pathways affected by these microRNAs. Altered miR-1237-3p expression was then found to be associated with clinicopathological characteristics and prognosis of spinal chordoma patients.
RESULTS: The miRNA arrays identified 29 differentially expressed miRNAs in spinal chordoma tissues, four of which were verified by qRT-PCR in 42 spinal chordomas and 14 control tissues. Bioinformatical analysis revealed that the potential target genes of these miRNAs were mainly involved in gene transcription, cell junction proteins, and gene pathways in cancer and endocytosis. Reduced miR-1237-3p expression was associated with tumor invasion and worse recurrence-free survival of spinal chordoma patients (χ (2) = 16.217, p = 0.000, log-rank test). Multivariate analyses showed that miR-1237-3p expression was an independent prognostic factor for patients with spinal chordoma (HR = 0.001, 95 % CI 0.000-0.136, p = 0.005).
CONCLUSION: The data from the current study identified a total of 29 differentially expressed miRNAs in chordoma tissues and reduced miR-1237-3p expression was associated with chordoma invasion and worse recurrence-free survival of the patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25850393     DOI: 10.1007/s00586-015-3927-9

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  40 in total

1.  Chordoma: incidence and survival patterns in the United States, 1973-1995.

Authors:  M L McMaster; A M Goldstein; C M Bromley; N Ishibe; D M Parry
Journal:  Cancer Causes Control       Date:  2001-01       Impact factor: 2.506

Review 2.  Endocytosis and cancer: an 'insider' network with dangerous liaisons.

Authors:  Letizia Lanzetti; Pier Paolo Di Fiore
Journal:  Traffic       Date:  2008-08-14       Impact factor: 6.215

3.  Operative management of sacral chordoma.

Authors:  Bruno Fuchs; Ian D Dickey; Michael J Yaszemski; Carrie Y Inwards; Franklin H Sim
Journal:  J Bone Joint Surg Am       Date:  2005-10       Impact factor: 5.284

Review 4.  Micro RNAs: tiny sequences with enormous potential.

Authors:  K Shruti; K Shrey; R Vibha
Journal:  Biochem Biophys Res Commun       Date:  2011-03-16       Impact factor: 3.575

Review 5.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

6.  Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.

Authors:  Carolina Vieira de Castro; Gustavo Guimaraes; Samuel Aguiar; Ademar Lopes; Glauco Baiocchi; Isabela Werneck da Cunha; Antonio Hugo Jose Froes Marques Campos; Fernando Augusto Soares; Maria Dirlei Begnami
Journal:  Hum Pathol       Date:  2013-04-22       Impact factor: 3.466

7.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

8.  Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.

Authors:  Reza Akhavan-Sigari; Michael Robert Gaab; Veit Rohde; Mehdi Abili; Helmut Ostertag
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

9.  Identification of nucleus pulposus precursor cells and notochordal remnants in the mouse: implications for disk degeneration and chordoma formation.

Authors:  Kyung-Suk Choi; Martin J Cohn; Brian D Harfe
Journal:  Dev Dyn       Date:  2008-12       Impact factor: 3.780

10.  Global and local architecture of the mammalian microRNA-transcription factor regulatory network.

Authors:  Reut Shalgi; Daniel Lieber; Moshe Oren; Yitzhak Pilpel
Journal:  PLoS Comput Biol       Date:  2007-07       Impact factor: 4.475

View more
  19 in total

1.  Chordoma: an update on the pathophysiology and molecular mechanisms.

Authors:  Xin Sun; Francis Hornicek; Joseph H Schwab
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Xiao-Bin Wang; Jing Li
Journal:  Eur Spine J       Date:  2016-10-18       Impact factor: 3.134

Review 3.  Chordoma of the Head and Neck: A Review.

Authors:  Jason K Wasserman; Denis Gravel; Bibianna Purgina
Journal:  Head Neck Pathol       Date:  2017-10-04

4.  Upregulated human telomerase reverse transcriptase (hTERT) expression is associated with spinal chordoma growth, invasion and poor prognosis.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 5.  Epigenetic deregulations in chordoma.

Authors:  Xin Yu; Zheng Li
Journal:  Cell Prolif       Date:  2015-08-10       Impact factor: 6.831

6.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

7.  Prognostic significance of MiR-34a in solid tumors: a systemic review and meta-analysis with 4030 patients.

Authors:  Fanghui Ren; Xin Zhang; Haiwei Liang; Dianzhong Luo; Minhua Rong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

8.  MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.

Authors:  Lisa Svartdal Normann; Miriam Ragle Aure; Suvi-Katri Leivonen; Mads Haugland Haugen; Vesa Hongisto; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

9.  MiR-17 and miR-93 Promote Tumor Progression by Targeting p21 in Patients with Chordoma.

Authors:  Wei Dong; Jingwu Li; Xiaoliu Dong; Wenjian Shi; Yu Zhang; Yongliang Liu
Journal:  Onco Targets Ther       Date:  2021-05-12       Impact factor: 4.147

10.  MiR-634 sensitizes glioma cells to temozolomide by targeting CYR61 through Raf-ERK signaling pathway.

Authors:  Zhigang Tan; Jizong Zhao; Yugang Jiang
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.